ALERT: COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits.

All Patients – Very Important: Regardless of vaccination status.  If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.  More Information-PLEASE CLICK HERE

Clinical Trial: 19144

Trial Status: Open
Disease Type: Prostate
Trial ID 19144
Sponsor ID

Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Principal Investigator
Ajay Dar, MD
5 Locations

Locations

Alexandria Office

Arlington Office

Fairfax Office

Gainesville Office

Loudoun Office

Learn More About This Trial
Other Relevant Trials
Trial ID 17-149
Sponsor ID

A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation

Principal Investigator
Daniel Chong, MD
4 Locations
Trial ID 15-247
Sponsor ID

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer (GU 115/I6A-MC-CBBD).

Principal Investigator
Daniel Chong, MD
1 Location